Navigation Links
FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
Date:2/29/2008

ISTIQ is contraindicated in patients with a known hypersensitivity to

PRISTIQ or venlafaxine.

-- PRISTIQ must not be used concomitantly with an MAOI or within 14 days

of stopping an MAOI. Allow 7 days after stopping PRISTIQ before

starting an MAOI.

Warnings and Precautions

-- All patients treated with antidepressants should be monitored

appropriately and observed closely for clinical worsening, suicidality,

and unusual changes in behavior, especially during the first few months

of treatment and when changing the dose. Consider changing the

therapeutic regimen, including possibly discontinuing the medication,

in patients whose depression is persistently worse or includes symptoms

of anxiety, agitation, panic attacks, insomnia, irritability,

hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or

suicidality that are severe, abrupt in onset, or were not part of the

patient's presenting symptoms. Families and caregivers of patients

being treated with antidepressants should be alerted about the need to

monitor patients.

-- Development of a potentially life-threatening serotonin syndrome may

occur with SNRIs and SSRIs, including PRISTIQ, particularly with

concomitant use of serotonergic drugs, including triptans. If

concomitant use is clinically warranted, careful observation of the

patient is advised, particularly during treatment initiation and dose

increases. Concomitant use of PRISTIQ with serotonin precursors is not

recommended.

-- Patients receiving PRISTIQ should have regular monitoring of blood

pressure since sustained increases in blood pressure were observed in

clinical studies. Pre-existing hypertension should be controlled before

starting PRISTIQ. Caution should be exercised in treating patients with


'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
2. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
3. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
4. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
5. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
6. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
9. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
10. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
11. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Dallas, Texas (PRWEB) July 28, 2014 ... Global and China Lubricant Industry” is a ... and Global Lubricant market. The report introduces ... application, and industry chain structure and industry ... analysis, including China’s domestic market as well ...
(Date:7/28/2014)... 28, 2014 Proove Biosciences , ... be exhibiting data and research conducted through their latest ... Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. The ... Hyatt Regency, in Orlando, Florida. , The ... competence of physicians who care for patients suffering specificity ...
(Date:7/28/2014)... , July 28, 2014 /PRNewswire/ -   JOLT , ... of companies to join its growing portfolio of startups. ... Toronto,s JOLT accelerator, and Cohort ... the roster. Since its launch in ... successfully raised  $7.5M of financing. Now at 23 investments, ...
(Date:7/28/2014)... NEW YORK , July 28, 2014 /PRNewswire/ ... for ConvergeHEALTH by Deloitte , has been ... Data Interchange Standards Consortium, a non-profit working to ... research data, particularly as it relates to electronic ... to continue CDISC,s mission of collaborating with organizations ...
Breaking Biology Technology:Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3
... 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" ... Phase II study of intravenous REOLYSIN(R) in patients with ... at the 15th Annual Connective Tissue Oncology Society Meeting ... 7th. The poster presentation, entitled "A Phase II Study ...
... . Fuel economy ratings for the new ... www.fueleconomy.gov web site, which Oak Ridge National Laboratory developed ... U.S. Environmental Protection Agency. Nine of the top 10 vehicles ... by the Toyota Prius (51 MPG city; 48 highway). "This ...
... , PARSIPPANY, N.J., Nov. 5 DSM Pharmaceutical Products ... with Galenix, Saint Jean D,Illac, France, where DSM will ... commercial products on a global basis. , DSM and ... drug delivery technologies, based on the strength of Galenix ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
(Date:7/28/2014)... Children,s Research Hospital study found that 73 percent of ... risk of developing metabolic syndrome and related health problems ... appear in the current issue of the journal ... adult survivors of childhood cancer in the study had ... like high blood pressure, abdominal obesity, elevated triglyceride and ...
(Date:7/28/2014)... prevent and treat HIV infection has been problematic until ... can arouse as they get rid of the invaders. ... Institute and the National Institutes of Health (NIH) have ... interferons around the time of infection could have ... research appeared in Nature . , Interferons, ...
(Date:7/27/2014)... study has revealed that nicotine and cotinine, a metabolite ... a certain carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone ... leaves and ultimately ends up in the tobacco smoke. ... liver, where it is activated by a variety of ... has revealed that nicotine can partially interfere with the ...
Breaking Biology News(10 mins):Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3Interfering with interferon 2Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2
... and metabolism, exerts a strong effect on appetite by ... the hypothalamus, according to a Yale School of Medicine ... regulate the ventral tegmental area (VTA) of the mid-brain ... of metabolic signals in the brain," said the senior ...
... technology for the first time ever to measure sexual arousal rates ... than men on its head. ... we see that there is no difference in the amount of ... arousal," said Dr. Irv Binik, psychology professor and founder and director ...
... of Medicine and Public Health has discovered a new part ... vessels, or angiogenesis. , The finding may help halt ... author on the study, a professor of pharmacology and member ... , The research, published in the Journal of Cell Biology ...
Cached Biology News:Thermal imaging shatters arousal gender gap myth 2New angiogenesis finding may help fight cancer growth 2New angiogenesis finding may help fight cancer growth 3New angiogenesis finding may help fight cancer growth 4
Normal serum collected from healthy Kunming mice....
Request Info...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
QML offers standard and customized paraffin embedded tissue blocks....
Biology Products: